Entera Bio Ltd. (ENTX)
Market Cap | 33.42M |
Revenue (ttm) | 134,000 |
Net Income (ttm) | -13.07M |
Shares Out | 28.81M |
EPS (ttm) | -0.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 66,039 |
Open | 1.17 |
Previous Close | 1.22 |
Day's Range | 1.11 - 1.23 |
52-Week Range | 0.47 - 3.00 |
Beta | 1.80 |
Analysts | Buy |
Price Target | 5.78 (+398.28%) |
Earnings Date | May 10, 2023 |
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreeme... [Read more]
Financial Performance
In 2022, Entera Bio's revenue was $134,000, a decrease of -76.53% compared to the previous year's $571,000. Losses were -$13.07 million, 7.25% more than in 2021.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $5.78, which is an increase of 398.28% from the latest price.
News

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

Entera Bio Regains Compliance with Nasdaq Listing Requirements
JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced t...

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

Entera Bio to Participate in the SVB Securities Global Biopharma Conference
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic p...

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

New Strong Buy Stocks for December 29th
SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.

New Strong Buy Stocks for November 21st
AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.

New Strong Buy Stocks for November 16th
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022.

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
- Total Hip BMD Established as Primary Endpoint - - Total Hip BMD Established as Primary Endpoint -

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today anno...

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today annou...

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announ...

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month op...

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the fol...

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phil...

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and op...

Follow the Insiders and Buy the Dip in These 3 Stocks
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S...

Entera Bio Reports Financial Results for the Year Ended December 31, 2021
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more ...